EP2190483A4 - Procédé visant à réduire les effets des médicaments cytostatiques sur les cellules dérivées de la moelle osseuse et procédés de criblage - Google Patents

Procédé visant à réduire les effets des médicaments cytostatiques sur les cellules dérivées de la moelle osseuse et procédés de criblage

Info

Publication number
EP2190483A4
EP2190483A4 EP08832037A EP08832037A EP2190483A4 EP 2190483 A4 EP2190483 A4 EP 2190483A4 EP 08832037 A EP08832037 A EP 08832037A EP 08832037 A EP08832037 A EP 08832037A EP 2190483 A4 EP2190483 A4 EP 2190483A4
Authority
EP
European Patent Office
Prior art keywords
screening
reducing
effects
methods
bone marrow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08832037A
Other languages
German (de)
English (en)
Other versions
EP2190483A1 (fr
Inventor
Jean-Francois Tanguay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ESTRACURE Inc
Original Assignee
ESTRACURE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ESTRACURE Inc filed Critical ESTRACURE Inc
Publication of EP2190483A1 publication Critical patent/EP2190483A1/fr
Publication of EP2190483A4 publication Critical patent/EP2190483A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08832037A 2007-09-20 2008-09-22 Procédé visant à réduire les effets des médicaments cytostatiques sur les cellules dérivées de la moelle osseuse et procédés de criblage Withdrawn EP2190483A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97393107P 2007-09-20 2007-09-20
PCT/CA2008/001677 WO2009036574A1 (fr) 2007-09-20 2008-09-22 Procédé visant à réduire les effets des médicaments cytostatiques sur les cellules dérivées de la moelle osseuse et procédés de criblage

Publications (2)

Publication Number Publication Date
EP2190483A1 EP2190483A1 (fr) 2010-06-02
EP2190483A4 true EP2190483A4 (fr) 2012-02-15

Family

ID=40467462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08832037A Withdrawn EP2190483A4 (fr) 2007-09-20 2008-09-22 Procédé visant à réduire les effets des médicaments cytostatiques sur les cellules dérivées de la moelle osseuse et procédés de criblage

Country Status (4)

Country Link
US (1) US20100247602A1 (fr)
EP (1) EP2190483A4 (fr)
CA (1) CA2711818A1 (fr)
WO (1) WO2009036574A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586338A2 (fr) * 2004-04-14 2005-10-19 Cordis Corporation Utilisation d'antioxydants pour la prévention d'oxydation et la réduction de la dégradation des principes actifs dans les articles médicaux libérant des principes actifs
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
US20070141109A1 (en) * 1999-09-21 2007-06-21 Baskaran Chadrasekar Local Deliver of 17-Beta Estradiol for Preventing Vascular Intimal Hyperplasia and for Improving Vascular Endothelium Function after Vascular Injury

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365811A1 (fr) * 2001-12-21 2003-06-21 Institut De Cardiologie Nouvelle therapie genique utilisant la strategie anti-sens pour les recepteurs estrogeniques (er .alpha. et/ou er .beta.) afin d'optimiser la regeneration vasculaire et la cardioprotection a la suite d'une lesion va sculaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141109A1 (en) * 1999-09-21 2007-06-21 Baskaran Chadrasekar Local Deliver of 17-Beta Estradiol for Preventing Vascular Intimal Hyperplasia and for Improving Vascular Endothelium Function after Vascular Injury
EP1586338A2 (fr) * 2004-04-14 2005-10-19 Cordis Corporation Utilisation d'antioxydants pour la prévention d'oxydation et la réduction de la dégradation des principes actifs dans les articles médicaux libérant des principes actifs
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADRIAENSSENS ET AL: "Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 49, no. 12, 26 March 2007 (2007-03-26), pages 1265 - 1271, XP022021831, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2007.02.021 *
ATSUSHI IWAKURA ET AL: "Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites ofischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 113, no. 12, 28 March 2006 (2006-03-28), pages 1605 - 1614, XP008131371, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.105.553925 *
BASKARAN CHANDRASEKAR ET AL: "Coronary artery endothelial protection after local delivery of 17[beta]-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 38, no. 5, 1 November 2001 (2001-11-01), pages 1570 - 1576, XP055015705, ISSN: 0735-1097, DOI: 10.1016/S0735-1097(01)01552-2 *
See also references of WO2009036574A1 *

Also Published As

Publication number Publication date
US20100247602A1 (en) 2010-09-30
EP2190483A1 (fr) 2010-06-02
WO2009036574A1 (fr) 2009-03-26
CA2711818A1 (fr) 2009-03-26

Similar Documents

Publication Publication Date Title
EP2124780A4 (fr) Implants pour apophyse épineuse et procédés associés
EP2131757A4 (fr) Système de découpe d'os maxillaire, kit, et procédé d'utilisation de celui-ci
EP2155084A4 (fr) Systèmes et procédés de traitement osseux
EP2219561A4 (fr) Implants vertébraux et procédés
EP2214597A4 (fr) Implants rachidiens et procédés
EP2142146A4 (fr) Implants interépineux et leurs procédés d'implantation
EP1877009A4 (fr) Implant spinal: appareil, procede et systeme
EP2001405A4 (fr) Dispositifs, systemes, et procedes pour fixation de materiau
EP2152205A4 (fr) Implant chirurgical à base de textile et procédés le concernant
EP2362753B8 (fr) Systèmes et procédés pour une fixation d'os interne
EP2137609A4 (fr) Système et procédé de mise à jour e composants fiables
EP1969989A4 (fr) Systeme d'introduction dans un sujet et procede d'observation de l'interieur d'un sujet
IL205778A0 (en) Medical system, apparatus and method
EP2240103A4 (fr) Système et procédé pour la fixation de fractures osseuses
IL205777A0 (en) Medical system, apparatus and method
EP2211742A4 (fr) Système de fixation chirugicale et procédés associés
EP2134299A4 (fr) Implants spinaux percutanés et procédés
EP1883709A4 (fr) Micro-arn humains et procedes d'inhibition de ceux-ci
EP2190366A4 (fr) Système de fixation chirurgical et procédés associés
ZA200605398B (en) Tibial insert and associated surgical method
EP1963500A4 (fr) Compositions comprenant des macromolecules immobilisees et orientees et leurs procedes de preparation
EP2114259A4 (fr) Méthode and système de fixation de tissus
EP1943938A4 (fr) Systeme endoscopique, endoscope, element porteur et procede d'utilisation
EP2399612A4 (fr) Composition pour marquer des tissus du système nerveux central, procédé pour marquer des tissus du système nerveux central, et procédé de criblage utilisant la composition pour marquer des tissus du système nerveux central
EP2207519A4 (fr) Système de mélange et procédé de mélange à des fins médicales

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 31/00 20060101ALI20120111BHEP

Ipc: A61K 45/06 20060101ALI20120111BHEP

Ipc: C12N 15/16 20060101ALI20120111BHEP

Ipc: C07K 14/72 20060101ALI20120111BHEP

Ipc: C12Q 1/02 20060101ALI20120111BHEP

Ipc: A61P 39/00 20060101ALI20120111BHEP

Ipc: A61P 35/00 20060101ALI20120111BHEP

Ipc: A61K 31/7088 20060101ALI20120111BHEP

Ipc: A61K 31/565 20060101ALI20120111BHEP

Ipc: A61K 31/436 20060101ALI20120111BHEP

Ipc: A61K 31/337 20060101ALI20120111BHEP

Ipc: A61K 48/00 20060101AFI20120111BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120403